The AWARD-7 trial, which is notable for its exclusive focus on patients with moderate-to-severe chronic kidney disease, demonstrated that dulaglutide users, particularly those simultaneously using ACE inhibitors or angiotensin receptor blockers, exhibited a substantially less eGFR decline compared to insulin glargine users
By providing personalized guidance and ongoing support, our team ensures that your health, confidence, and overall well-being remain a priority throughout your treatment
This article examines FDA guidance, clinical trial data, and current medical practice regarding semaglutide treatment duration
Idiopathic intracranial hypertension without papilledema: a case-control study in a headache center
Drinking plenty of water throughout the day helps counteract any fluid loss from gastrointestinal side effects and can alleviate headaches and fatigue